ClinicalTrials.gg
CompletedNCT04602598Updated Apr 1, 2026Results posted

Zanubrutinib in Patients With IgG4-Related Disease

A Phase 2 interventional study of Zanubrutinib 80 MG in IgG4 Related Disease, sponsored by Matthew C. Baker. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Matthew C. Baker · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Immunoglobulin G4-Related Disease with a site in United States — 3 open to participants now, 7 under way, 3 of them phase 3. Immunoglobulin G4-Related Disease · United States.

Enrollment
8th of 12
10 · median 18
Started
2022
the only one that year
Phase 2
7 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
1 of 14
Matthew C. Baker

Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 8th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

3 of the 14 studies in Immunoglobulin G4-Related Disease with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Immunoglobulin G4-Related Disease with a site in United States, or all of them as a file.
02

Study summary

The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease

Read the detailed description

This will be a single-site, open-label study in symptomatic patients with IgG4-related disease affecting the submandibular and/or lacrimal glands. All patients will receive zanubrutinib orally at a dose of 80mg BID for 24 weeks.

The primary objective of this study is to demonstrate that zanubrutinib treatment reduces reduces the volume of the submandibular and/or lacrimal glands on PET/MRI at week 24 compared to baseline.

03

Conditions studied

  • IgG4 Related Disease
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 to 85, inclusive, at the time of initial screening
  • Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the lacrimal gland confirmed by international consensus pathology criteria

    • Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%
  • All women must test negative for pregnancy and agree to use a reliable method of
  • No current treatment with medications other than prednisone 40mg daily (or other equivalent) with stable dosing for 28 days

Exclusion criteria

Exclusion Criteria:

  • Unstable prescribed dose of within 28 days prior to baseline
  • Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine, methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline
  • Any treatment with a cytotoxic or drug including but not limited to cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or tacrolimus within 28 days prior to baseline
  • Any treatment with a BTK inhibitor within 6 months before baseline
  • Any treatment with a JAK inhibitor within 28 days prior to baseline
  • Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days prior to baseline
  • Use of a B cell depleting therapy (such as rituximab) within 12 months prior to baseline
  • A history of, or current, inflammatory or disease (that could affect the interpretation of safety or efficacy outcomes) other than IgG4-related disease
  • Evidence of active tuberculosis, , or or C infection
  • History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma in situ (cured >1 year), prostate cancer (cured >5 years), or colon cancer (cured >5 years)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Zanubrutinib orally at a dose of 80mg BID for 24 weeks

    Drug: Zanubrutinib 80 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Volume of the Submandibular Glands on PET-MRI

    To demonstrate that zanubrutinib treatment reduces the volume of the submandibular glands on PET-MRI at week 24 compared to Baseline.

    Time frame: Baseline and Week 24

  2. Volume of the Lacrimal Glands on PET-MRI

    To demonstrate that zanubrutinib treatment reduces the volume of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. FDG Avidity (SUVmax) of the Submandibular Glands on PET

    Effect of zanubrutinib on change in FDG avidity (SUVmax) of the submandibular glands on PET at Weeks 12 and 24 compared to Baseline.

    Time frame: Baseline, Week 12, and Week 24

  2. FDG Avidity (SUVmax) of the Lacrimal Glands on PET

    Effect of zanubrutinib on change in FDG avidity (SUVmax) of the lacrimal glands on PET at Week 24 compared to Baseline.

    Time frame: Baseline, Week 12, and Week 24

  3. Change in Total Metabolic Lesion Volume (tMLV) of Lacrimal Glands, Submandibular Glands, Parotid Glands, and Lymph Notes on PET

    Time frame: Baseline, Week 12, and Week 24

  4. Change in Total Lesion Glycolysis (TLG) of Submandibular and/or Lacrimal Glands on PET

    Time frame: Baseline, Week 12, and Week 24

  5. Change in Submandibular Glands on MRI

    Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4 where 0 is normal, healthy gland and 4 is worse outcome.

    Time frame: Baseline, Week 12, and Week 24

  6. Change in Parotid Glands on MRI

    Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.

    Time frame: Baseline, Week 12, and Week 24

  7. Change in Lacrimal Glands on MRI

    Change in parenchymal architecture scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.

    Time frame: Baseline, Week 12, and Week 24

  8. Change in the Volume of the Parotid Glands on PET/MRI

    Time frame: Baseline, Week 12, and Week 24

  9. Change in the Volume of the Submandibular Glands on PET/MRI

    Time frame: Baseline and Week 12

  10. Change in the Volume of the Lacrimal Glands on PET/MRI

    Time frame: Baseline, and Week 12

  11. Change in Serum IgG4 Level

    Time frame: Baseline, Week 12, and Week 24

  12. Change in Plasmablast Count

    Change in percentage of CD19+ B cells in blood

    Time frame: Baseline, Week 12, and Week 24

  13. Change in Absolute Regulatory B Cell Count

    Percentage of regulatory B cells in the blood, assessed using flow cytometry.

    Time frame: Baseline, Week 12, and Week 24

  14. Change in the IgG4-RD Responder Index

    The IgG4-RD Responder Index detects change in disease activity and identifies improvements/worsening in the same or different organ systems. It encompasses more than 25 organs/sites and records the following for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. The final activity score at each visit is obtained by summing all organ/site scores (i) and by doubling items needing urgent care (iii). The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.

    Time frame: Baseline, Week 12, and Week 24

  15. Proportion of Patients With no Disease Flares

    Number and percentage of patients who did not have an IgG4-RD flare

    Time frame: Week 12 to Week 24

  16. Change in Total Salivary Grey Scale Ultrasound Score (TUS)

    Each parotid and submandibular gland scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

    Time frame: Baseline, Week 12, and Week 24

  17. Change in Highest Score Among the Salivary Glands for the Grey Scale Ultrasound Score (HSUS)

    Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

    Time frame: Baseline, Week 12, and Week 24

  18. Change in Glandular Inflammation Total Ultrasound Score (iTUS)

    Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

    Time frame: Baseline, Week 12, and Week 24

  19. Change in Highest Score Among the Salivary Glands for the Glandular Inflammation Ultrasound Score (iHSUS)

    Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

    Time frame: Baseline, Week 12, and Week 24

  20. Change in Physician Global Assessment of Disease

    Symptoms rated on a 100 mm visual analog scale (VAS). Score range: 0 to 100, higher scores correspond to worse disease state.

    Time frame: Baseline, Week 12, and Week 24

  21. Change in Patient Global Assessment of Disease

    Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.

    Time frame: Baseline, Week 12, and Week 24

  22. Change in VAS for Ocular Symptoms - Dryness

    Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.

    Time frame: Baseline to Week 24

  23. Change in VAS for Dryness Symptoms

    Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to more dryness. Participants were asked to assess their dryness, taking into account all areas, including ocular and salivary symptoms.

    Time frame: Baseline, Week 12, Week 24

  24. Change in FACIT-F Fatigue Score

    Total score range: 0-52, lower scores correspond with more fatigue. FACIT = Functional Assessment of Chronic Illness Therapy.

    Time frame: Baseline, Week 12, and Week 24

  25. Change in RAND Short Form-36

    The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.

    Time frame: Baseline, Week 12, and Week 24

  26. Change in C3 Lab

    Complement component 3 (C3) level in blood

    Time frame: Baseline, Week 12, and Week 24

  27. Change in C4 Lab

    Complement component 4 (C4) level in blood

    Time frame: Baseline, Week 12, and Week 24

  28. Change in Total IgG Lab

    Time frame: Baseline, Week 12, and Week 24

  29. Change in IgE Lab

    Time frame: Baseline, Week 12, and Week 24

  30. Change in IgG1 Lab

    Time frame: Baseline, Week 12, and Week 24

  31. Change in ESR Lab

    Change in erythrocyte sedimentation rate (ESR)

    Time frame: Baseline, Week 12, and Week 24

  32. Change in CRP Lab

    Change in serum C-reactive protein (CRP) level

    Time frame: Baseline, Week 12, and Week 24

  33. Incidence of Safety Parameters Including Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs).

    Time frame: Baseline to Week 32

  34. Incidence of Safety Parameters Including Abnormal Laboratory Results

    Number of participants with any grade 3 or 4 treatment-emergent laboratory abnormality

    Time frame: Baseline to Week 32

07

Results

Posted Apr 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneZanubrutinib
Started10
Completed week 12 imaging8
Completed week 24 imaging7
Completed7
Not completed3

Outcome measures

PrimaryVolume of the Submandibular Glands on PET-MRI

To demonstrate that zanubrutinib treatment reduces the volume of the submandibular glands on PET-MRI at week 24 compared to Baseline.

Time frame:
Baseline and Week 24
Reported as:
Mean · cm^3
Volume of the Submandibular Glands on PET-MRI
cm^3Zanubrutinib
Baseline12.7 ± 5.78
Week 249.34 ± 4.80
Change from Baseline at Week 24-3.37 ± 2.40
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
PrimaryVolume of the Lacrimal Glands on PET-MRI

To demonstrate that zanubrutinib treatment reduces the volume of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.

Time frame:
Baseline and Week 24
Reported as:
Mean · cm^3
Volume of the Lacrimal Glands on PET-MRI
cm^3Zanubrutinib
Baseline2.59 ± 2.18
Week 241.17 ± 0.520
Change from Baseline at Week 24-1.42 ± 1.76
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
SecondaryFDG Avidity (SUVmax) of the Submandibular Glands on PET

Effect of zanubrutinib on change in FDG avidity (SUVmax) of the submandibular glands on PET at Weeks 12 and 24 compared to Baseline.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · kg/L
FDG Avidity (SUVmax) of the Submandibular Glands on PET
kg/LZanubrutinib
Baseline5.33 ± 3.77
Week 123.42 ± 1.26
Change from Baseline at Week 12-1.91 ± 3.14
Week 243.27 ± 1.05
Change from Baseline at Week 24-2.06 ± 3.41
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.03 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.05 (The a priori threshold for statistical significance is \<0.05.)
SecondaryFDG Avidity (SUVmax) of the Lacrimal Glands on PET

Effect of zanubrutinib on change in FDG avidity (SUVmax) of the lacrimal glands on PET at Week 24 compared to Baseline.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · kg/L
FDG Avidity (SUVmax) of the Lacrimal Glands on PET
kg/LZanubrutinib
Baseline5.52 ± 2.48
Week 123.37 ± 1.18
Change from Baseline at Week 12-2.15 ± 2.45
Week 243.23 ± 1.27
Change from Baseline at Week 24-2.29 ± 2.90
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.008 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.01 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Total Metabolic Lesion Volume (tMLV) of Lacrimal Glands, Submandibular Glands, Parotid Glands, and Lymph Notes on PET
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · cm^3
Change in Total Metabolic Lesion Volume (tMLV) of Lacrimal Glands, Submandibular Glands, Parotid Glands, and Lymph Notes on PET
cm^3Zanubrutinib
Baseline24.3 ± 20.6
Week 125.19 ± 2.10
Change from Baseline at Week 12-19.2 ± 20.5
Week 243.64 ± 2.56
Change from Baseline at Week 24-20.7 ± 22.4
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.04 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.05 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Total Lesion Glycolysis (TLG) of Submandibular and/or Lacrimal Glands on PET
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · grams
Change in Total Lesion Glycolysis (TLG) of Submandibular and/or Lacrimal Glands on PET
gramsZanubrutinib
Baseline103 ± 92.1
Week 1216.1 ± 7.54
Change from Baseline at Week 12-86.7 ± 91.3
Week 2411.2 ± 9.91
Change from Baseline at Week 24-91.6 ± 98.5
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.04 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.05 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Submandibular Glands on MRI

Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4 where 0 is normal, healthy gland and 4 is worse outcome.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Submandibular Glands on MRI
score on a scaleZanubrutinib
Baseline (architecture)1.13 ± 0.500
Week 12 (architecture)1.25 ± 0.577
Change from Baseline at Week 12 (architecture)0.125 ± 0.342
Week 24 (architecture)1.38 ± 0.806
Change from Baseline at Week 24 (architecture)0.250 ± 0.683
Baseline (saliography)1.00 ± 0
Week 12 (saliography)1.00 ± 0
Change from Baseline at Week 12 (sialography)0 ± 0
Week 24 (sialography)1.00 ± 0
Change from Baseline at Week 24 (sialography)0 ± 0
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.3 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.3 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Parotid Glands on MRI

Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Parotid Glands on MRI
score on a scaleZanubrutinib
Baseline (architecture)2.13 ± 0.957
Week 12 (architecture)1.63 ± 0.719
Change from Baseline at Week 12 (architecture)-0.500 ± 0.730
Week 24 (architecture)1.63 ± 0.719
Change from Baseline at Week 24 (architecture)-0.500 ± 0.730
Baseline (sialography)1.13 ± 0.342
Week 12 (sialography)1.13 ± 0.342
Change from Baseline at Week 12 (sialography)0 ± 0
Week 24 (sialography)1.13 ± 0.342
Change from Baseline at Week 24 (sialography)0 ± 0
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.03 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.03 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Lacrimal Glands on MRI

Change in parenchymal architecture scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Lacrimal Glands on MRI
score on a scaleZanubrutinib
Baseline2.13 ± 1.09
Week 122.50 ± 0.894
Change from Baseline at Week 120.375 ± 0.500
Week 242.69 ± 0.946
Change from Baseline at Week 240.563 ± 0.814
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.03 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in the Volume of the Parotid Glands on PET/MRI
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · cm^3
Change in the Volume of the Parotid Glands on PET/MRI
cm^3Zanubrutinib
Baseline44.6 ± 14.6
Week 1239.6 ± 11.6
Change from Baseline at Week 12-5.07 ± 5.04
Week 2438 ± 11.7
Change from Baseline at Week 24-6.66 ± 5.04
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in the Volume of the Submandibular Glands on PET/MRI
Time frame:
Baseline and Week 12
Reported as:
Mean · cm^3
Change in the Volume of the Submandibular Glands on PET/MRI
cm^3Zanubrutinib
Baseline12.7 ± 5.78
Week 1210.0 ± 4.97
Change from Baseline at Week 12-2.69 ± 2.35
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in the Volume of the Lacrimal Glands on PET/MRI
Time frame:
Baseline, and Week 12
Reported as:
Mean · cm^3
Change in the Volume of the Lacrimal Glands on PET/MRI
cm^3Zanubrutinib
Baseline2.59 ± 2.18
Week 121.50 ± 0.89
Change from Baseline at Week 12-1.09 ± 1.38
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in the Volume of the Parotid Glands on PET/MRI
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · cm^3
Change in the Volume of the Parotid Glands on PET/MRI
cm^3Zanubrutinib
Baseline44.6 ± 14.6
Week 1239.6 ± 11.6
Change from Baseline at Week 12-5.07 ± 5.04
Week 2438 ± 11.7
Change from Baseline at Week 24-6.66 ± 5.04
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = < 0.001 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Serum IgG4 Level
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · mg/dL
Change in Serum IgG4 Level
mg/dLZanubrutinib
Baseline643 ± 567
Week 12342 ± 305
Change from Baseline at Week 12-301 ± 278
Week 24226 ± 179
Change from Baseline at Week 24-413 ± 443
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.008 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02
SecondaryChange in Plasmablast Count

Change in percentage of CD19+ B cells in blood

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · percentage of cells
Change in Plasmablast Count
percentage of cellsZanubrutinib
Baseline17.8 ± 25.2
Week 120.175 ± 0.205
Change from Baseline at Week 12-17.6 ± 25.1
Week 240.213 ± 0.259
Change from Baseline at Week 24-19.6 ± 26.5
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.008 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Absolute Regulatory B Cell Count

Percentage of regulatory B cells in the blood, assessed using flow cytometry.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · percentage of cells
Change in Absolute Regulatory B Cell Count
percentage of cellsZanubrutinib
Baseline3.03 ± 2.53
Week 120.538 ± 1.03
Change from Baseline at Week 12-2.49 ± 2.40
Week 240.450 ± 0.404
Change from Baseline at Week 24-2.58 ± 2.39
SecondaryChange in the IgG4-RD Responder Index

The IgG4-RD Responder Index detects change in disease activity and identifies improvements/worsening in the same or different organ systems. It encompasses more than 25 organs/sites and records the following for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. The final activity score at each visit is obtained by summing all organ/site scores (i) and by doubling items needing urgent care (iii). The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · units on a scale
Change in the IgG4-RD Responder Index
units on a scaleZanubrutinib
Baseline6.63 ± 0.916
Week 122.38 ± 2.07
Change from Baseline at Week 12-4.25 ± 2.49
Week 242.00 ± 2.20
Change from Baseline at Week 24-4.63 ± 2.62
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02 (The a priori threshold for statistical significance is \<0.05.)
SecondaryProportion of Patients With no Disease Flares

Number and percentage of patients who did not have an IgG4-RD flare

Time frame:
Week 12 to Week 24
Reported as:
Count of participants · Participants
Proportion of Patients With no Disease Flares
ParticipantsZanubrutinib
Proportion of Patients With no Disease Flares7
SecondaryChange in Total Salivary Grey Scale Ultrasound Score (TUS)

Each parotid and submandibular gland scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Total Salivary Grey Scale Ultrasound Score (TUS)
score on a scaleZanubrutinib
Baseline5.3 ± 3.8
Week 124.4 ± 3.0
Change from Baseline at Week 12-0.88 ± 1.25
Week 243.5 ± 1.9
Change from Baseline at Week 24-1.75 ± 2.19
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.1 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.06 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Highest Score Among the Salivary Glands for the Grey Scale Ultrasound Score (HSUS)

Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Highest Score Among the Salivary Glands for the Grey Scale Ultrasound Score (HSUS)
score on a scaleZanubrutinib
Baseline2.3 ± 0.71
Week 121.9 ± 0.84
Change from Baseline at Week 12-0.38 ± 0.52
Week 241.6 ± 0.74
Change from Baseline at Week 24-0.63 ± 0.52
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.1 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.04 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Glandular Inflammation Total Ultrasound Score (iTUS)

Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Glandular Inflammation Total Ultrasound Score (iTUS)
score on a scaleZanubrutinib
Baseline7.4 ± 2.7
Week 126.4 ± 1.6
Change from Baseline at Week 12-1.00 ± 1.77
Week 245.3 ± 1.5
Change from Baseline at Week 24-2.13 ± 2.70
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.2 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.07 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Highest Score Among the Salivary Glands for the Glandular Inflammation Ultrasound Score (iHSUS)

Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Highest Score Among the Salivary Glands for the Glandular Inflammation Ultrasound Score (iHSUS)
score on a scaleZanubrutinib
Baseline2.4 ± 0.92
Week 122.1 ± 0.84
Change from Baseline at Week 12-0.25 ± 0.46
Week 241.8 ± 0.71
Change from Baseline at Week 24-0.63 ± 0.74
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.3 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.09 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Physician Global Assessment of Disease

Symptoms rated on a 100 mm visual analog scale (VAS). Score range: 0 to 100, higher scores correspond to worse disease state.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Physician Global Assessment of Disease
score on a scaleZanubrutinib
Baseline68.4 ± 12.7
Week 1221.4 ± 29.4
Change from Baseline at Week 12-47.0 ± 27.8
Week 2417.4 ± 29.3
Change from Baseline at Week 24-51.0 ± 28.3
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Patient Global Assessment of Disease

Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in Patient Global Assessment of Disease
score on a scaleZanubrutinib
Baseline52.4 ± 19.6
Week 1238.4 ± 30.4
Change from Baseline at Week 12-14.0 ± 27.1
Week 2431.0 ± 25.8
Change from Baseline at Week 24-21.4 ± 26.6
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.2 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.05 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in VAS for Ocular Symptoms - Dryness

Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.

Time frame:
Baseline to Week 24
Reported as:
Mean · score on a scale
Change in VAS for Ocular Symptoms - Dryness
score on a scaleZanubrutinib
Baseline47.6 ± 25.3
Week 1231.9 ± 20.9
Change from Baseline at Week 12-15.8 ± 28.9
Week 2421.5 ± 15.1
Change from Baseline at Week 24-26.1 ± 32.7
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.2 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.1 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in VAS for Dryness Symptoms

Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to more dryness. Participants were asked to assess their dryness, taking into account all areas, including ocular and salivary symptoms.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · score on a scale
Change in VAS for Dryness Symptoms
score on a scaleZanubrutinib
Baseline47.6 ± 25.3
Week 1231.9 ± 20.9
Change from Baseline at Week 12-15.8 ± 28.9
Week 2421.5 ± 15.1
Change from Baseline at Week 24-26.1 ± 32.7
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.2 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.1 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in FACIT-F Fatigue Score

Total score range: 0-52, lower scores correspond with more fatigue. FACIT = Functional Assessment of Chronic Illness Therapy.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in FACIT-F Fatigue Score
score on a scaleZanubrutinib
Baseline38.9 ± 14.0
Week 1241.6 ± 9.12
Change from Baseline at Week 122.75 ± 10.4
Week 2443.3 ± 5.80
Change from Baseline at Week 244.38 ± 11.6
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.9 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.5 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in RAND Short Form-36

The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · score on a scale
Change in RAND Short Form-36
score on a scaleZanubrutinib
Baseline85.6 ± 15.5
Week 1278.8 ± 30.3
Change from Baseline at Week 12-6.88 ± 23.0
Week 2478.1 ± 29.1
Change from Baseline at Week 24-7.50 ± 21.9
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.8 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.5 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in C3 Lab

Complement component 3 (C3) level in blood

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · mg/dL
Change in C3 Lab
mg/dLZanubrutinib
Baseline116 ± 29.0
Week 12114 ± 16.7
Change from Baseline at Week 121.86 ± 22.3
Week 24121 ± 23.7
Change from Baseline at Week 246.43 ± 21.4
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.5 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.8 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in C4 Lab

Complement component 4 (C4) level in blood

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · mg/dL
Change in C4 Lab
mg/dLZanubrutinib
Baseline28.6 ± 14.1
Week 1231.5 ± 8.93
Change from Baseline at Week 122.88 ± 9.51
Week 2431.0 ± 8.00
Change from Baseline at Week 242.00 ± 11.6
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.6 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.9 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in Total IgG Lab
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · mg/dL
Change in Total IgG Lab
mg/dLZanubrutinib
Baseline1610 ± 578
Week 121240 ± 286
Change from Baseline at Week 12-368 ± 345
Week 241200 ± 316
Change from Baseline at Week 24-395 ± 570
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.008 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.1 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in IgE Lab
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · kU/L
Change in IgE Lab
kU/LZanubrutinib
Baseline562 ± 396
Week 121230 ± 1070
Change from Baseline at Week 12672 ± 965
Week 241280 ± 1010
Change from Baseline at Week 24544 ± 817
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.3 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.2 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in IgG1 Lab
Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · mg/dL
Change in IgG1 Lab
mg/dLZanubrutinib
Baseline572 ± 106
Week 12491 ± 67.0
Change from Baseline at Week 12-80.8 ± 65.2
Week 24505 ± 125
Change from Baseline at Week 24-71.2 ± 109
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.02 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.2 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in ESR Lab

Change in erythrocyte sedimentation rate (ESR)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · mm/hr
Change in ESR Lab
mm/hrZanubrutinib
Baseline20.4 ± 19.7
Week 129.00 ± 5.26
Change from Baseline at Week 12-11.4 ± 15.9
Week 248.75 ± 3.85
Change from Baseline at Week 24-12.9 ± 18.6
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.06 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 0.1 (The a priori threshold for statistical significance is \<0.05.)
SecondaryChange in CRP Lab

Change in serum C-reactive protein (CRP) level

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Mean · mg/dL
Change in CRP Lab
mg/dLZanubrutinib
Baseline0.313 ± 0.0354
Week 120.313 ± 0.0354
Change from Baseline at Week 120 ± 0.0535
Week 240.300 ± 0
Change from Baseline at Week 24-0.0143 ± 0.0378
Statistical analysis
  • Zanubrutinib · Wilcoxon signed-rank test · p = 1 (The a priori threshold for statistical significance is \<0.05.)
  • Zanubrutinib · Wilcoxon signed-rank test · p = 1 (The a priori threshold for statistical significance is \<0.05.)
SecondaryIncidence of Safety Parameters Including Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs).

Time frame:
Baseline to Week 32
Reported as:
Count of participants · Participants
Incidence of Safety Parameters Including Adverse Events
ParticipantsZanubrutinib
TEAE10
TEAE with Grade 3 or Higher2
TEAE Related to Study Drug8
TEAE Related to Study Drug with Grade 3 or Higher1
TE Serious AE1
TE Serious AE Related to Study Drug0
TEAE Leading to Premature Discontinuation of Study Drug2
TEAE Leading to Premature Discontinuation of Study2
SecondaryIncidence of Safety Parameters Including Abnormal Laboratory Results

Number of participants with any grade 3 or 4 treatment-emergent laboratory abnormality

Time frame:
Baseline to Week 32
Reported as:
Count of participants · Participants
Incidence of Safety Parameters Including Abnormal Laboratory Results
ParticipantsZanubrutinib
Incidence of Safety Parameters Including Abnormal Laboratory Results2

Adverse events

Collected over Up to 32 weeks (24 weeks treatment plus 8 weeks follow-up). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib0/10 (0%)1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventZanubrutinib
COVID-19Infections and infestations1/10
Most frequent other events
Showing 10 of 24
Most frequent other events
EventZanubrutinib
Upper respiratory tract infectionInfections and infestations4/10
Neutrophil count decreasedBlood and lymphatic system disorders2/10
COVID-19Infections and infestations1/10
LeukocytosisBlood and lymphatic system disorders1/10
EosinophiliaBlood and lymphatic system disorders1/10
AnemiaBlood and lymphatic system disorders1/10
HematuriaRenal and urinary disorders1/10
RashSkin and subcutaneous tissue disorders1/10
UrticariaSkin and subcutaneous tissue disorders1/10
Bullous pemphigoidSkin and subcutaneous tissue disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zanubrutinib
Mean58.2 ± 11.4
Age, Customized
Age, Customized(Participants)Zanubrutinib
<50 years3
>=50 years7
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib
Female3
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zanubrutinib
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zanubrutinib
Asian6
Black1
White2
Other1
Region of Enrollment
Region of Enrollment(Participants)Zanubrutinib
United States10
08

Study locations

1 site
  • Stanford University
    Palo Alto, California 94304, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Feb 2025, 30 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2020
First posted
Oct 26, 2020
StartActual
Aug 1, 2022
Primary completionActual
Feb 11, 2025
CompletionActual
Apr 3, 2025
Results first posted
Apr 1, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04602598
Lead sponsor
Matthew C. Baker
Collaborators
Stanford University
Responsible party
Matthew C. Baker (Assistant Professor, Stanford University) — Sponsor-investigator
First posted
Oct 26, 2020
Start date
Aug 1, 2022
Primary completion
Feb 11, 2025
Completion
Apr 3, 2025
Results posted
Apr 1, 2026
Last update
Apr 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion